(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/257409 A1

(51) International Patent Classification:
A61K 38/47 (2006.01) *A61P 43/00* (2006.01)
A61K 47/26 (2006.01)

(21) International Application Number:
PCT/US2021/037111

(22) International Filing Date:
11 June 2021 (11.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/038,857	14 June 2020 (14.06.2020)	US
63/076,037	09 September 2020 (09.09.2020)	US
63/147,629	09 February 2021 (09.02.2021)	US
63/157,490	05 March 2021 (05.03.2021)	US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 50 Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **FINN, Patrick**; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). **HAMED, Alaa**; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). **AN HAACK, Kristina**; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). **WILSON, Catherine**; c/o Catherine Wilson Physical Therapy, LLC, 918 Green Street, Durham, NC 27701 (US).

(74) Agent: **QI, Yan** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR TREATING LATE-ONSET POMPE DISEASE




FIG. 11

(57) Abstract: The present application provides methods of treating late-onset Pompe disease (LOPD) using a pharmaceutical composition comprising an oligosaccharide-acid α-glucosidase (GAA) conjugate, such as avalglucosidase alfa.

WO 2021/257409 A1

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*